Xenon (XENE) Stock Forecast & Price Target

Compare

403 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XENE Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Xenon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XENE Stock 12 Month Forecast

Average Price Target

$54.96

▲(24.74% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Xenon in the last 3 months. The average price target is $54.96 with a high forecast of $65.00 and a low forecast of $44.00. The average price target represents a 24.74% change from the last price of $44.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","66":"$66","38.25":"$38.3","47.5":"$47.5","56.75":"$56.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,38.25,47.5,56.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.51,45.16307692307692,46.816153846153846,48.46923076923077,50.12230769230769,51.77538461538462,53.428461538461534,55.08153846153846,56.73461538461538,58.387692307692305,60.04076923076923,61.69384615384615,63.346923076923076,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.51,44.39076923076923,45.27153846153846,46.15230769230769,47.03307692307692,47.91384615384615,48.79461538461538,49.675384615384615,50.55615384615385,51.43692307692308,52.31769230769231,53.19846153846154,54.07923076923077,{"y":54.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.51,43.54769230769231,43.58538461538461,43.62307692307692,43.660769230769226,43.69846153846154,43.73615384615385,43.77384615384615,43.81153846153846,43.84923076923077,43.886923076923075,43.924615384615386,43.96230769230769,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$54.96

Lowest Price Target$44.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

―

Buy

―

Reiterated

12/11/25

Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Results Justify Buy Rating

Benjamin Burnett

Wells Fargo

$44→$48

Buy

8.94%

Upside

Reiterated

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$44

Buy

-0.14%

Downside

Reiterated

12/11/25

Xenon (XENE) Receives a Buy from Wedbush

Tessa Romero

J.P. Morgan

$57→$60

Buy

36.18%

Upside

Reiterated

11/18/25

Xenon Pharmaceuticals price target raised to $60 from $57 at JPMorganXenon Pharmaceuticals price target raised to $60 from $57 at JPMorgan

Douglas Tsao

H.C. Wainwright

$40.04→$53

Buy

20.29%

Upside

Reiterated

11/14/25

H.C. Wainwright Sticks to Their Buy Rating for Xenon (XENE)

Jason Gerberry

Bank of America Securities

$49→$50

Buy

13.48%

Upside

Reiterated

11/04/25

Xenon (XENE) Gets a Buy from Bank of America SecuritiesWe reiterate Buy and $50 PO

Cory Kasimov

Evercore ISI

$55

Buy

24.83%

Upside

Reiterated

11/04/25

Xenon (XENE) Receives a Buy from Evercore ISI

Paul Matteis

Stifel Nicolaus

$60

Buy

36.18%

Upside

Reiterated

11/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (NASDAQ: XENE), Syndax Pharmaceuticals (NASDAQ: SNDX) and Inspire Medical Systems (NYSE: INSP)

Serge Belanger

Needham

$55

Buy

24.83%

Upside

Assigned

11/04/25

Analysts Are Bullish on Top Healthcare Stocks: Krystal Biotech (KRYS), Xenon (XENE)

Brian Abrahams

RBC Capital

$55→$58

Buy

31.64%

Upside

Reiterated

11/04/25

Xenon Pharmaceuticals price target raised to $58 from $55 at RBC CapitalXenon Pharmaceuticals price target raised to $58 from $55 at RBC Capital

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/03/25

Xenon Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating

Rudy Li

Chardan Capital

$55

Buy

24.83%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA), Xenon (NASDAQ: XENE) and Arcus Biosciences (NYSE: RCUS)We reiterate our Buy rating and $55 PT.

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Remains a Buy on Xenon (XENE)

Andrew Tsai

Jefferies

$65

Buy

47.53%

Upside

Reiterated

10/07/25

Xenon (XENE) Receives a Buy from Jefferies

David Martin PhD

Bloom Burton

$56.5

Buy

28.23%

Upside

Reiterated

10/07/25

Promising Outlook on Xenon Pharmaceuticals: Buy Rating Backed by Innovative Pain Treatment Developments11:49 AM F r o m : Research S e n t : 1:55 PM S u b j e c t : Xenon Pharmaceucals Inc. (NASDAQ:XENE, $39.55). Webinar Encouraging. Both have advanced into phase 1 testing in healthy volunteers with results expected next year. Trial design was not discussed in detail, however, results should include safety/tolerability, PK and possibly PD and induced pain response endpoints. Based on the emerging profiles of XEN1120 and XEN1701, both could be attractive in multiple pain settings including acute and chronic nociceptive (tissue injury) as well as neuropathic (nervous system dysfunction) pain - together affecting 125-130 million individuals in the U.S.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

―

Buy

―

Reiterated

12/11/25

Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Results Justify Buy Rating

Benjamin Burnett

Wells Fargo

$44→$48

Buy

8.94%

Upside

Reiterated

12/11/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$44

Buy

-0.14%

Downside

Reiterated

12/11/25

Xenon (XENE) Receives a Buy from Wedbush

Tessa Romero

J.P. Morgan

$57→$60

Buy

36.18%

Upside

Reiterated

11/18/25

Xenon Pharmaceuticals price target raised to $60 from $57 at JPMorganXenon Pharmaceuticals price target raised to $60 from $57 at JPMorgan

Douglas Tsao

H.C. Wainwright

$40.04→$53

Buy

20.29%

Upside

Reiterated

11/14/25

H.C. Wainwright Sticks to Their Buy Rating for Xenon (XENE)

Jason Gerberry

Bank of America Securities

$49→$50

Buy

13.48%

Upside

Reiterated

11/04/25

Xenon (XENE) Gets a Buy from Bank of America SecuritiesWe reiterate Buy and $50 PO

Cory Kasimov

Evercore ISI

$55

Buy

24.83%

Upside

Reiterated

11/04/25

Xenon (XENE) Receives a Buy from Evercore ISI

Paul Matteis

Stifel Nicolaus

$60

Buy

36.18%

Upside

Reiterated

11/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (NASDAQ: XENE), Syndax Pharmaceuticals (NASDAQ: SNDX) and Inspire Medical Systems (NYSE: INSP)

Serge Belanger

Needham

$55

Buy

24.83%

Upside

Assigned

11/04/25

Analysts Are Bullish on Top Healthcare Stocks: Krystal Biotech (KRYS), Xenon (XENE)

Brian Abrahams

RBC Capital

$55→$58

Buy

31.64%

Upside

Reiterated

11/04/25

Xenon Pharmaceuticals price target raised to $58 from $55 at RBC CapitalXenon Pharmaceuticals price target raised to $58 from $55 at RBC Capital

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/03/25

Xenon Pharmaceuticals: Promising Pipeline and Strong Financial Position Justify Buy Rating

Rudy Li

Chardan Capital

$55

Buy

24.83%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (NASDAQ: BMEA), Xenon (NASDAQ: XENE) and Arcus Biosciences (NYSE: RCUS)We reiterate our Buy rating and $55 PT.

Marc Goodman

Leerink Partners

―

Buy

―

Reiterated

10/07/25

Leerink Partners Remains a Buy on Xenon (XENE)

Andrew Tsai

Jefferies

$65

Buy

47.53%

Upside

Reiterated

10/07/25

Xenon (XENE) Receives a Buy from Jefferies

David Martin PhD

Bloom Burton

$56.5

Buy

28.23%

Upside

Reiterated

10/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xenon

1 Month

xxx

Success Rate

9/10 ratings generated profit

Average Return

+8.57%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 90.00% of your transactions generating a profit, with an average return of +8.57% per trade.

3 Months

xxx

Success Rate

7/10 ratings generated profit

Average Return

+9.14%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +9.14% per trade.

1 Year

Andrew TsaiJefferies

Success Rate

15/17 ratings generated profit

Average Return

+31.86%

reiterated a buy rating 2 months ago

Copying Andrew Tsai's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +31.86% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+10.23%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +10.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XENE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XENE has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XENE average Analyst price target in the past 3 months is 54.96.

Each month's total comprises the sum of three months' worth of ratings.

XENE Financial Forecast

XENE Earnings Forecast

Next quarter’s earnings estimate for XENE is -$1.19 with a range of -$1.38 to -$0.99. The previous quarter’s EPS was -$1.15. XENE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.

XENE Sales Forecast

Next quarter’s sales forecast for XENE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. XENE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.

XENE Stock Forecast FAQ

What is XENE’s average 12-month price target, according to analysts?

Based on analyst ratings, Xenon’s 12-month average price target is 54.96.

What is XENE’s upside potential, based on the analysts’ average price target?

Xenon has 24.74% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is XENE a Buy, Sell or Hold?

Xenon has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Xenon’s price target?

The average price target for Xenon is 54.96. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $44.00. The average price target represents 24.74% Increase from the current price of $44.06.

What do analysts say about Xenon?

Xenon’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of XENE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Xenon (XENE) Stock Forecast & Price Target

XENE Analyst Ratings

XENE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Xenon

XENE Analyst Recommendation Trends

XENE Financial Forecast

XENE Earnings Forecast

XENE Sales Forecast

XENE Stock Forecast FAQ

Detailed List of Analyst Forecasts